Articles by Blood Cancers Today Staff Writers
Real-world data shows evolving treatment strategies and clinical decision-making.
Tafasitamab achieved a real-world overall response rate of 73.5%, with a median duration of response of 9.6 months.
Researchers are launching a new clinical trial that will evaluate the combination of glofitamab with pirtobrutinib in MCL.
A new study has identified genetic factors that can affect the molecular pathways involved in treatment response.
QuANTUM-Wild has begun treatment administration in patients with newly-diagnosed FLT3-ITD+ AML.
VGT-1849A is aJAK2 inhibitor that is designed to have less off-target suppression of JAK1, JAK3, TYK2, and other kinases.
Dr. Matthew Cortese reported that CAR T-cell therapy appears to overcome some of the adverse prognostic impact.
The study used a standard 3+3 dose escalation design to evaluate the results of SYNCAR-001 plus STK-009.
HMAs, either as monotherapy or in combination with venetoclax, represent the standard of care for higher-risk MDS or AML.
Moving forward, prospective studies must validate these findings and refine risk stratification tools like the IPSS-R in MDS.
Outcomes for patients with AML and MDS who experience relapse after alloHSCT are poor.
Overall, fedratinib 400 mg daily was a safe MTD for post-HSCT maintenance therapy for participants with MPN.
Some patients with ZRSR2-mutated CCUS had concurrent blood cancers or disorders, and others had protective co-mutation.
Findings suggest a potential metabolic benefit of pacritinib, warranting further investigation in myelofibrosis.
The PROMise trial aims to examine the safety and preliminary efficacy of OPN-2853 with ruxolitinib for MF treatment.
An ongoing phase 1 study is evaluating the safety and efficacy of danvatirsen through two substudies.
HMA plus venetoclax may achieve higher response rates and improve event-free survival in high-risk MDS.
In a murine mitochondrial succinate dehydrogenase knockdown model of low-risk MDS luspatercept alleviated anemia.
New WHO and ICC 022 guidelines propose lowering the threshold for diagnosis of CMML.
High-risk MDS is associated with poor outcomes, making the assessment of treatment response critical.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.